Silo Pharma, Inc.
NASDAQ Capital MarketTotal Valuation
Silo Pharma, Inc. carries a market capitalization of 5.52M, placing it among publicly traded companies globally. Its enterprise value stands at -2.76M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.52M |
| Enterprise Value | -2.76M |
Share Statistics
Silo Pharma, Inc. currently has 1.08M shares outstanding.
| Shares Outstanding | 1.08M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 48.80, and the price-to-book ratio stands at -0.17.
| PE Ratio | N/A |
| PS Ratio | 48.80 |
| PB Ratio | -0.17 |
| P/TBV Ratio | 0.64 |
| P/FCF Ratio | -0.93 |
| P/OCF Ratio | -0.92 |
Enterprise Valuation
| EV / Sales | 1,682.88 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Silo Pharma, Inc. maintains a current ratio of 9.65, meaning it holds 9.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 9.65 |
| Quick Ratio | 8.90 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -123.54 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -74.99 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Silo Pharma, Inc.'s stock has declined approximately -32.29745% over the past 52 weeks. The 50-day moving average sits at 6.25, while the 200-day moving average is 6.60.
| Beta (5Y) | N/A |
| 52-Week Price Change | -32.29745% |
| 50-Day Moving Average | 6.25 |
| 200-Day Moving Average | 6.60 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Silo Pharma, Inc. generated 72,102.00 in revenue and converted that into -4.84M in net income, yielding earnings per share of -7.43. EBITDA reached -4.77M, while operating income came in at -4.78M.
| Revenue | 72,102.00 |
| Gross Profit | 8,579.00 |
| Operating Income | -4.78M |
| Pretax Income | -4.84M |
| Net Income | -4.84M |
| EBITDA | -4.77M |
| EBIT | -4.78M |
| Earnings Per Share (EPS) | -7.43 |
Balance Sheet
Total book value stands at -21.14M, with working capital of 6.10M providing operational flexibility.
| Cash & Cash Equivalents | 6.27M |
| Total Debt | N/A |
| Net Debt | -3.90M |
| Equity (Book Value) | -21.14M |
| Book Value Per Share | -32.44 |
| Working Capital | 6.10M |
Cash Flow
Silo Pharma, Inc. produced -3.84M in operating cash flow over the past twelve months. After subtracting -49,990.00 in capital expenditures, free cash flow totaled -3.89M - equivalent to -5.98 per share.
| Operating Cash Flow | -3.84M |
| Capital Expenditures | -49,990.00 |
| Free Cash Flow | -3.89M |
| FCF Per Share | -5.98 |
Margins
Silo Pharma, Inc. operates with a gross margin of 11.90, reflecting its pricing power and cost economics. The operating margin of -6,631.16 and net profit margin of -6,717.40 provide insight into operational efficiency.
| Gross Margin | 11.90 |
| Operating Margin | -6,631.16 |
| Pretax Margin | -6,717.40 |
| Profit Margin | -6,717.40 |
| EBITDA Margin | -6,615.51 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -138.14 |
| FCF Yield | -107.82 |
Stock Splits
Silo Pharma, Inc.'s most recent stock split took place on June 3, 2026 with a 15:1 split ratio.
| Last Split Date | 6/3/2026 |
| Split Ratio | 15:1 |
Scores
Silo Pharma, Inc. posts an Altman Z-Score of -4.00, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -4.00 |